Investors Show Strong Interest in Hexagon Nutrition IPO, Bids Reach 54 Times

Date:

Share post:

Hexagon Nutrition Limited, a leading research-driven nutrition company, concluded its Initial Public Offering (IPO) with resounding success, achieving an overall subscription of 53.68 times on the third and final day of bidding. The company’s ₹139-crore public issue attracted robust investor interest, generating total bids for 1,15,96,08,897 shares against the 2,16,02,008 shares on offer.

The bidding was heavily anchored by Non-Institutional Investors (NIIs), whose  fetched a massive 161.49 times subscription. Individual retail investors also turned out in strong numbers, booking their allocated quota 26.85 times. TheQualified Institutional Buyers (QIBs) recorded a healthy subscription of 19.77 times. Ahead of the public opening, Hexagon Nutrition had already successfully raised ₹41.66 crore from major anchor investors at the upper price band.

The initial public offering was presented within a price band fixed at ₹42 to ₹45 per equity share. The public issue comprised entirely of an Offer for Sale (OFS) of over 3.08 crore equity shares offloaded by the company’s promoters. Hexagon Nutrition has stated that the objectives of this proposed listing are to significantly enhance its corporate visibility, strengthen overall brand recognition, and provide exit opportunities to its existing shareholders.

Founded in 1993, Hexagon Nutrition began its journey as a specialized micronutrient formulations business and later strategically diversified into the high-growth branded nutrition space. Recently, its extensive consumer portfolio features trusted household brands such as Pentasure, Obesigo, Pediagold, and Nutrone across the health, wellness, and clinical nutrition segments. The company also acts as a vital B2B partner, supplying customized vitamin and mineral premixes to leading global FMCG firms.

Backed by advanced in-house R&D capabilities and manufacturing facilities located in both India and Uzbekistan, Hexagon Nutrition maintains a robust global footprint, exporting its product lines to over 75 countries. Following the closure of the bidding window, the company’s equity shares are scheduled to debut and commence trading on the premier domestic stock exchanges (BSE and NSE) on June 12.

Written by : Pragna Biswas

Graphics by: Mainak Sen

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Johnson & Johnson to acquire Firefly Bio to advance novel cancer treatment

Johnson & Johnson  announced that it has entered into a definitive agreement to acquire Firefly Bio, Inc., a...

Emergency Price Adjustment Approved for Critical Cancer Drugs Amid Raw Material Crisis

In a decisive move to counter critical domestic medicine shortages caused by global macroeconomic headwinds, the Department of...

India Targets 100 New Biologic Medicines by 2047 Under Biopharma SHAKTI

At the landmark 2nd Pharma Summit & Awards 2026 organized by the Associated Chambers of Commerce and Industry...

AstraZeneca Advances Oral GLP-1 Elecoglipron to Phase III Programme

AstraZeneca  announced positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an investigational oral small molecule glucagon-like peptide-1...